Immunoglobulin E blockade in the treatment of asthma

Pharmacotherapy

Volumn 27, Issue 10, 2007, Pages 1412-1424

  Kuhn, Robert ^a  

^a University of Kentucky   (United States)

Author keywords

Antiinflammatory asthma; Corticosteroids; Dosing; IgE; Immunoglobulin E; Omalizumab

Indexed keywords

ALLERGEN; ANTIBIOTIC AGENT; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE; IMMUNOGLOBULIN E; LEUKOTRIENE RECEPTOR BLOCKING AGENT; OMALIZUMAB; SALMETEROL; THEOPHYLLINE;

ANAPHYLAXIS; ASTHMA; CLINICAL TRIAL; DRUG APPROVAL; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HUMAN; INFLAMMATION; INJECTION SITE REACTION; LUNG FUNCTION; MALIGNANT NEOPLASTIC DISEASE; MAST CELL; MONEY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHARYNGITIS; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; SINUSITIS; SYMPTOM; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; HUMANS; IMMUNOGLOBULIN E; MODELS, IMMUNOLOGICAL; PROTEIN BINDING; RECEPTORS, IGE;

EID: 34948812529     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.10.1412     Document Type: Review

References (116)

1. National Asthma Education and Prevention Program. Expert panel report 2: guidelines for the diagnosis and management of asthma. No. 02-5075. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health; 1997.
2. American Lung Association, Epidemiology and Statistics Unit, Research and Program Services. Trends in asthma morbidity and mortality, May 2005. Available from www.lungusa.org/atf/cf/%7b7a8d42c2-fcca-4604-8ade- 7f5d5e762256%7d/asthma1.pdf. Accessed August 4, 2006.
3. Dolan CM, Fraher KE, Bleecker ER, et al. Design and baseline characteristics of the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004;92(1):32-9.
4. Milgrom H, Bender B, Ackerson L, Bowry P, Smith B, Rand C. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol 1996;98(6 pt 1):1051-7.
5. Cochrane MG, Bala MV, Downs KE, Mauskopf J, Ben-Joseph RH. Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. Chest 2000;117(2):542-50.
6. Bender B, Wamboldt FS, O'Connor SL, et al. Measurement of children's asthma medication adherence by self report, mother report, canister weight, and doser CT. Ann Allergy Asthma Immunol 2000;85(5):416-21.
7. Apter AJ, Boston RC, George M, et al. Modifiable barriers to adherence to inhaled steroids among adults with asthma: it's not just black and white. J Allergy Clin Immunol 2003;111(6):1219-26.
8. Williams LK, Pladevall M, Xi H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol 2004;114(6):1288-93.
9. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med 2004;170(8):836-44.
10. Harding SM. Gastroesophageal reflux: a potential asthma trigger. Immunol Allergy Clin North Am 2005;25(1):131-48.
11. Nakase H, Itani T, Mimura J, et al. Relationship between asthma and gastroesophageal reflux: significance of endoscopic grade of reflux esophagitis in adult asthmatics. J Gastroenterol Hepatol 1999;14(7):715-22.
12. Loza Cortina C. Severe steroid-dependent asthma with 1gG-2 deficiency and recurrent sinusitis: response to treatment with high-dose intravenous immunoglobulin. Allergol Immunopathol (Madr) 1999;27(3):165-7.
13. Newman KB, Mason UG III, Schmaling KB. Clinical features of vocal cord dysfunction. Am J Respir Crit Care Med 1995;152(4 pt 1):1382-6.
14. Fletcher D, Mainardi JL, Brun-Buisson C, Lemaire F, Brochard L. Cardiac asthma presenting as status asthmaticus: deleterious effect of epinephrine therapy. Intensive Care Med 1990;16(7):466-8.
15. Bresciani M, Paradis L, Des Roches A, et al. Rhinosinusitis in severe asthma. J Allergy Clin Immunol 2001;107(1):73-80.
16. Corren J, Adinoff AD, Buchmeier AD, Irvin CG. Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma. J Allergy Clin Immunol 1992;90(2):250-6.
17. Corren J, Adinoff AD, Irvin CG. Changes in bronchial responsiveness following nasal provocation with allergen. J Allergy Clin Immunol 1992;89(2):611-18.
18. MacDowell AL, Bacharier LB. Infectious triggers of asthma. Immunol Allergy Clin North Am 2005;25(1):45-66.
19. Smart BA, Slavin RG. Rhinosinusitis and pediatric asthma. Immunol Allergy Clin North Am 2005;25(1):67-82.
20. Erwin EA, Platts-Mills TA. Allergens. Immunol Allergy Clin North Am 2005;25(1):1-14.
21. Tatum AJ, Shapiro GG. The effects of outdoor air pollution and tobacco smoke on asthma. Immunol Allergy Clin North Am 2005;25(1):15-30.
22. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma: update on selected topics 2002. No. 02-5074. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health; 2003.
23. Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992;90(1):32-42.
24. Trigg CJ, Manolitsas ND, Wang J, et al. Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. Am J Respir Crit Care Med 1994;150(1):17-22.
25. Haahtela T, Jarvinen M, Kava T, et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991;325(6):388-92.
26. Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O'Byrne PM, Hargreave FE. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990;142(4):832-6.
27. Sin DD, Man SF. Low-dose inhaled corticosteroid therapy and risk of emergency department visits for asthma. Arch Intern Med 2002;162(14):1591-5.
28. Donahue JG, Weiss ST, Livingston JM, Goetsch MA, Greineder DK, Platt R. Inhaled steroids and the risk of hospitalization for asthma. JAMA 1997;277(11):887-91.
29. Suissa S, Ernst P. Inhaled corticosteroids: impact on asthma morbidity and mortality. J Allergy Clin Immunol 2001;107(6):937-44.
30. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000;343(5):332-6.
31. Szefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002;109(3):410-18.
32. Welch MJ, Levy S, Smith JA, Feiss G, Farrar JR. Dose-ranging study of the clinical efficacy of twice-daily triamcinolone acetonide inhalation aerosol in moderately severe asthma. Chest 1997;112(3):597-606.
33. Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ 2001;323(7307):253-6.
34. FitzGerald JM, Becker A, Sears MR, Mink S, Chung K, Lee J. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 2004;59(7):550-6.
35. Masoli M, Holt S, Weatherall M, Beasley R. Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis. Eur Respir J 2004;23(4):552-8.
36. Masoli M, Weatherall M, Holt S, Beasley R. Clinical dose-response relationship of fluticasone propionate in adults with asthma. Thorax 2004;59(1):16-20.
37. Fukushima C, Matsuse H, Tomari S, et al. Oral candidiasis associated with inhaled corticosteroid use: comparison of fluticasone and beclomethasone. Ann Allergy Asthma Immunol 2003;90(6):646-51.
38. Williamson IJ, Matusiewicz SP, Brown PH, Greening AP, Crompton GK. Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations. Eur Respir J 1995;8(4):590-2.
39. Mortimer KJ, Harrison TW, Tattersfield AE. Effects of inhaled corticosteroids on bone. Ann Allergy Asthma Immunol 2005;94(1):15-21.
40. Hubbard RB, Smith CJ, Smeeth L, Harrison TW, Tattersfield AE. Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med 2002;166(12 pt 1):1563-6.
41. Allen DB, Bielory L, Derendorf H, Dluhy R, Colice GL, Szefler SJ. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 2003;112(3 suppl):S1-40.
42. Brown PH, Blundell G, Greening AP, Crompton GK. Hypothalamo-pituitary-adrenal axis suppression in asthmatics inhaling high dose corticosteroids. Respir Med 1991;85(6):501-10.
43. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med 1999;159(9):941-55.
44. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129(1):15-26.
45. U.S. Food and Drug Administration. FDA public health advisory, Serevent Diskus (salmeterol xinafoate inhalation powder), Advair Diskus (fluticasone propionate & salmeterol inhalation powder), and Foradil Aerolizer (formoterol fumarate inhalation powder). Available from www.fda.gov/cder/drug/advisory/LABA.htm. Accessed February 1, 2006.
46. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000;320(7246):1368-73.
47. Currie GP, Srivastava P, Dempsey OJ, Lee DK. Therapeutic modulation of allergic airways disease with leukotriene receptor antagonists. OJM 2005;98(3):171-82.
48. Busse W, Kraft M. Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. Chest 2005;127(4):1312-26.
49. Ducharme F, Schwartz Z, Kakuma R. Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2004;(1):CD003133.
50. Ducharme FM. Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence. BMJ 2002;324(7353):1545.
51. Ducharme FM, Di Salvio F. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 2004;(1):CD002314.
52. Zeiger RS, Szefler SJ, Phillips BR, et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol 2006;117(1):45-52.
53. Currie GP, Lee DK, Srivastava P. Long-acting bronchodilator or leukotriene modifier as add-on therapy to inhaled corticosteroids in persistent asthma? Chest 2005;128(4):2954-62.
54. Seddon P, Bara A, Ducharme F, Lasserson T. Oral xanthines as maintenance treatment for asthma in children. Cochrane Database Syst Rev 2006;(1):CD002885.
55. Dahl R, Larsen BB, Venge P. Effect of long-term treatment with inhaled budesonide or theophylline on lung function, airway reactivity and asthma symptoms. Respir Med 2002;96(6):432-8.
56. Wang Y, Wang CZ, Lin KX, et al. Comparison of inhaled corticosteroid combined with theophylline and double-dose inhaled corticosteroid in moderate to severe asthma. Respirology 2005;10(2):189-95.
57. Tsuchida T, Matsuse H, Machida I, et al. Evaluation of theophylline or pranlukast, a cysteinyl leukotriene receptor 1 antagonist, as add-on therapy in uncontrolled asthmatic patients with a medium dose of inhaled corticosteroids. Allergy Asthma Proc 2005;26(4):287-91.
58. Yurdakul AS, Calisir HC, Tunctan B, Ogretensoy M. Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma. Respir Med 2002;96(5):322-9.
59. Shah L, Wilson AJ, Gibson PG, Coughlan J. Long acting beta-agonists versus theophylline for maintenance treatment of asthma. Cochrane Database Syst Rev 2003;(3):CD001281.
60. Brownell J, Casale TB. Anti-IgE therapy. Immunol Allergy Clin North Am 2004;24(4):551-68.
61. Platts-Mills TA. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med 2001;164(8 pt 2):S1-5.
62. Poole JA, Matangkasombut P, Rosenwasser LJ. Targeting the IgE molecule in allergic and asthmatic diseases: review of the IgE molecule and clinical efficacy. J Allergy Clin Immunol 2005;115(3):S376-85.
63. Ferreira MA. inflammation in allergic asthma: initiating events, immunological response and risk factors. Respirology 2004;9(1):16-24.
64. MacGlashan D Jr, McKenzie-White J, Chichester K, et al. In vitro regulation of FcepsilonRI alpha expression on human basophils by IgE antibody. Blood 1998;91(5):1633-43.
65. Yamaguchi M, Lantz CS, Oettgen HC, et al. IgE enhances mouse mast cell Fc(epsilon)RI expression in vitro and in vivo: evidence for a novel amplification mechanism in IgE-dependent reactions. J Exp Med 1997;185(4):663-72.
66. Yamaguchi M, Sayama K, Yano K, et al. IgE enhances Fc epsilon receptor I expression and IgE-dependent release of histamine and lipid mediators from human umbilical cord blood-derived mast cells: synergistic effect of IL-4 and IgE on human mast cell Fc epsilon receptor 1 expression and mediator release. J Immunol 1999;162(9):5455-65.
67. Turner H, Kinet JP. Signaling through the high-affinity IgE receptor Fc epsilonRI. Nature 1999;402(6760 suppl):B24-30.
68. Kisselgof AB, Oettgen HC. The expression of murine B cell CD23, in vivo, is regulated by its ligand, IgE. Int Immunol 1998;10(9):1377-84.
69. Yano K, Yamaguchi M, de Mora F, et al. Production of macrophage inflammatory protein-1alpha by human mast cells: increased anti-IgE-dependent secretion after IgE-dependent enhancement of mast cell IgE-binding ability. Lab Invest 1997;77(2):185-93.
70. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989;320(5):271-7.
71. Sunyer J, Anto JM, Castellsague J, Soriano JB, Roca J. Total serum IgE is associated with asthma independently of specific IgE levels. The Spanish group of the European study of asthma. Eur Respir J 1996;9(9):1880-4.
72. Sears MR, Burrows B, Flannery EM, Herbison GP, Hewitt CJ, Holdaway MD. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 1991;325(15):1067-71.
73. Sherrill DL, Stein R, Halonen M, Holberg CJ, Wright A, Martinez FD. Total serum IgE and its association with asthma symptoms and allergic sensitization among children. J Allergy Clin Immunol 1999;104(1):28-36.
74. Borish L, Chipps B, Deniz Y, Gujrathi S, Zheng B, Dolan CM. Total serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2005;95(3):247-53.
75. Bousquet J, Coulomb Y, Arrendal H, Robinet-Levy M, Michel FB. Total serum IgE concentrations in adolescents and adults using the phadebas IgE PRIST technique. Allergy 1982;37(6):397-406.
76. Wittig HJ, Belloit J, De Fillippi I, Royal G. Age-related serum immunoglobulin E levels in healthy subjects and in patients with allergic disease. J Allergy Clin Immunol 1980;66(4):305-13.
77. Klink M, Cline MG, Halonen M, Burrows B. Problems in defining normal limits for serum IgE. J Allergy Clin Immunol 1990;85(2):440-4.
78. Kerkhof M, Dubois AE, Postma DS, Schouten JP, de Monchy JG. Role and interpretation of total serum IgE measurements in the diagnosis of allergic airway disease in adults. Allergy 2003;58(9):905-11.
79. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the joint task force on practice parameters in allergy, asthma and immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998;81(5 pt 2):478-518.
80. Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol 1993;151(5):2623-32.
81. MacGlashan DW Jr, Bochner BS, Adelman DC, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158(3):1438-45.
82. Lin H, Boesel KM, Griffith DT, et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol 2004;113(2):297-302.
83. Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumab-induced reductions in mast cell Fcepsilon RI expression and function. J Allergy Clin Immunol 2004;114(3):527-30.
84. Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 2003;112(6):1147-54.
85. Genentech Inc. Xolair (omalizumab for subcutaneous use) package insert. South San Francisco, CA; 2003.
86. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108(2):184-90.
87. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18(2):254-61.
88. Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003;91(2):154-9.
89. Buhl R, Soler M, Matz J, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002;20(1):73-8.
90. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;59(7):701-8.
91. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60(3):309-16.
92. Milgrom H, Fick RB Jr, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody: rhuMAb-E25 study group. N Engl J Med 1999;341(26):1966-73.
93. Barnes PJ. Anti-IgE antibody therapy for asthma. N Engl J Med 1999;341(26):2006-8.
94. Holgate ST, Chuchalin AG, Hebert J, et al. Efficacy and safely of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34(4):632-8.
95. Holgate S, Bousquet J, Wenzel S, Fox H, Liu J, Castellsague J. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin 2001;17(4):233-40.
96. Corren J, Casale T, Deniz Y, Ashby M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 2003;111(1):87-90.
97. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60(3):302-8.
98. Buhl R, Hanf G, Soler M, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002;20(5):1088-94.
99. Finn A, Gross G, van Bavel J, et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 2003;111(2):278-84.
100. Luskin AT, Kosinski M, Bresnahan BW, Ashby M, Wong DA. Symptom control and improved functioning: the effect of omalizumab on asthma-related quality of life (ARQL). J Asthma 2005;42(10):823-7.
101. Niebauer K, Dewilde S, Fox-Rushby J, Revicki DA. Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma. Ann Allergy Asthma Immunol 2006;96(2):316-26.
102. Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 2003;131(1):46-52.
103. Djukanovic R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004;170(6):583-93.
104. Noga O, Hanf G, Brachmann I, et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 2006;117(6):1493-9.
105. Huang YC, Leyko B, Frieri M. Effects of omalizumab and budesonide on markers of inlfammation in human bronchial epithelial cells. Ann Allergy Asthma Immunol 2005;95(5):443-51.
106. Ong YE, Menzies-Gow A, Barkans J, et al. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. J Allergy Clin Immunol 2005;116(3):558-64.
107. Deniz YM, Gupta N. Safety and tolerability of omalizumab (Xolair®), a recombinant humanized monoclonal anti-IgE antibody. Clin Rev Allergy Immunol 2005;29(1):31-48.
108. Rieves D. BLA STN 103976/0. Review of clinical safety data. Original BLA submitted June 2, 2000 and response to complete review letter submitted on December 18, 2002. Genentech, Inc. Omalizumab (Xolair™) (recombinant humanized monoclonal antibody to IgE) for treatment of allergic asthma. June 20, 2003. Available from www.fda.gov/cder/biologics/review/ omalgen062003r1.pdf. Accessed July 31, 2006.
109. U.S. Food and Drug Administration Center for Drug Evaluation and Research. Omalizumab (marketed as Xolair) information: FDA alert. Available from http://www.fda.gov/cder/drug/infopage/omalizumab/default.htm. Accessed July 13, 2007.
110. Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med 2006;354(25):2689-95.
111. Belliveau PP, Lahoz MR. Evaluation of omalizumab from a health plan perspective. J Manag Care Pharm 2005;11(9):735-45.
112. Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol 2004;114(2):265-9.
113. Asche CV, Brixner DI, Oderda GM. Has the cost-effectiveness of Xolair (omalizumab) been underestimated? J Allergy Clin Immunol 2005;115(5):1095; author reply 1095-6.
114. Dewilde S, Turk F, Tambour M, Sandstrom T. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin 2006;22(9):1765-76.
115. Global Initiative for Asthma. Global strategy for asthma management and prevention. No. 02-3659. Bethesda, MD: National Heart, Lung and Blood Institute, National Institutes of Health; 2004.
116. Global Initiative for Asthma. Pocket guide for asthma management and prevention. Updated from global strategy for asthma management and prevention. No. 02-3659. Bethesda, MD: National Heart, Lung and Blood Institute, National Institutes of Health; 2005.